Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

• F. Javier Ibarrondo ,

  * E-mail: fibarrondo@mednet.ucla.edu (FJI); bcomin@mednet.ucla.edu (BC-A)

  Affiliations Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, UCLA AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Otto O. Yang,

  Affiliations UCLA AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Thinle Chodon,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Earl Avramis,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Yohan Lee,

  Affiliation Department of Child Psychiatry Branch, NIH/NIMH, Bethesda, Maryland, Untied States of America

  ⨯
• Hooman Sazegar,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Jason Jalil,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Bartosz Chmielowski,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Richard C. Koya,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Ingrid Schmid,

  Affiliation Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Jesus Gomez-Navarro,

  Current address: Millennium: The Takeda Oncology Company, Cambridge, Massachusetts, United States of America

  Affiliation Department of Clinical Research, Pfizer Global Research and Development (PGRD), New London, Connecticut, United States of America

  ⨯
• Beth D. Jamieson,

  Affiliations UCLA AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

  ⨯
• Antoni Ribas,

  Affiliations Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Begoña Comin-Anduix

  * E-mail: fibarrondo@mednet.ucla.edu (FJI); bcomin@mednet.ucla.edu (BC-A)

  Affiliations Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯